lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy

Glioblastoma (GBM) is the most common and lethal type of primary malignant central nervous system (CNS) tumor with an extremely poor prognosis, and the mesenchymal subtype of GBM has the worst prognosis. Here, we found that lncRNA PRADX was overexpressed in the mesenchymal GBM and was transcriptiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Can, Zhao, Jixing, Song, Jia, Xiao, Menglin, Cui, Xiaoteng, Xin, Lei, Xu, Jianglong, Zhang, Yuhao, Yi, Kaikai, Hong, Biao, Tong, Fei, Tian, Shaohui, Tan, Yanli, Kang, Chunsheng, Fang, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106305/
https://www.ncbi.nlm.nih.gov/pubmed/35574370
http://dx.doi.org/10.3389/fonc.2022.888922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106305/
https://www.ncbi.nlm.nih.gov/pubmed/35574370
http://dx.doi.org/10.3389/fonc.2022.888922

Ejemplares similares